Avenacy's Participation at the ASHP Midyear Clinical Meeting
Avenacy, a leading specialty pharmaceutical company committed to delivering critical injectable medications, has announced its plans to attend the upcoming 2024 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition. This important event will take place in a vibrant setting, providing a unique opportunity for Avenacy to connect with industry professionals and stakeholders.
Showcasing Growth and Innovations
During the ASHP Midyear Meeting, Avenacy is excited to showcase the impressive progress it has made since its inception. The company aims to highlight its innovative business model and the expertise of its leadership team. Visitors to the Avenacy exhibit, located at booth #1029, can engage with company representatives to discuss their extensive portfolio of injectable medications and learn more about the company's growth plans.
A Commitment to Patient Care
Since launching, Avenacy has introduced 14 essential injectable medicines to the market, with ambitions to expand its product lineup to over 25 by the end of 2025. The company prides itself on collaborating with a wide network of development and manufacturing partners across the globe, ensuring a robust pipeline of FDA-approved products that cater to diverse medical needs. These medicines are critical for patient treatment in settings that include acute care hospitals and outpatient clinics.
Enhancing Safety Through Innovation
Avenacy stands out in its dedication to patient safety and medication administration accuracy. Each product is equipped with unique packaging and labeling that aids healthcare providers in selecting the correct medication, thereby reducing the risk of dosing errors and enhancing overall patient safety. Furthermore, Avenacy offers ready-to-use formulations that simplify the administration process while ensuring precise dosing.
About Avenacy
Founded in 2023 and based in Schaumburg, IL, Avenacy is both a pioneer and a trusted partner in the specialty pharmaceutical sector. The company specializes in supplying critical injectable medicines while maintaining a focus on high quality and reliability. Through a careful selection process, Avenacy curates a strong portfolio of FDA-approved injectable products that meets the evolving demands of today’s healthcare providers.
Future Aspirations of Avenacy
Avenacy is strategically positioned to play a key role in the pharmaceutical industry by expanding its offerings and enhancing access to vital medications. The company’s commitment to innovation and patient care underpins its mission, and with an experienced team at the helm, Avenacy is poised for significant advances in the coming years.
Frequently Asked Questions
What is Avenacy focusing on at the ASHP meeting?
Avenacy will showcase its injectable medication portfolio and discuss its innovative business model.
How many injectable medicines has Avenacy launched?
Avenacy has launched 14 injectable medicines and plans to expand to over 25 products.
Where is Avenacy's exhibit located at the conference?
Avenacy's exhibit will be at booth #1029 at the ASHP Midyear Meeting.
What is Avenacy's mission?
The mission of Avenacy is to provide reliable, high-quality injectable medications to enhance patient care.
When was Avenacy established?
Avenacy was established in 2023 and is based in Schaumburg, IL.
